Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Oral Levosimendan on Ambulatory Electrocardiographic Parameters in Patients After Ischaemic Cerebrovascular Event
2007-007197-31Phase 2Completed
- Sponsor
- Orion Corporation
- Start
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of levosimendan in ischemic stroke and transient ischaemic attack (TIA), sponsored by Orion Corporation. Primary endpoint: Ventricular extrasystoles per hour (VES/h) in 24-hour ambulatory ECG (Holter). Started Mar 2008; status: completed.
02
Drugs
levosimendan
03
Conditions
ischemic stroketransient ischaemic attack (TIA)
Beyond the preview
Go deeper on 2007-007197-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007197-31.